Related Experiment Video
Updated: Feb 8, 2026

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Development of vaccine for Clostridium difficile infection using membrane fraction of nontoxigenic Clostridium
Mitsutoshi Senoh1, Masaaki Iwaki1, Akihiko Yamamoto2
1Department of Bacteriology II, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.
Abstract:
Although standard antibiotic therapy is performed for diarrhea and pseudomembranous colitis caused by Clostridium difficile, a high recurrence rate of C. difficile infection (CDI) remains a major problem. We previously showed that a membrane fraction of nontoxigenic C. difficile (ntCDMF) was effective as a vaccine antigen by in vitro experiments. In this study, we examined whether ntCDMF had an in vivo effect in animal challenge experiments. By intrarectal immunization with ntCDMF, the number of C. difficile cells in feces of mice was decreased approximately 99% compared to the control mice. In addition, survival rate of C. difficile-challenged hamsters was increased almost 30% by immunization with ntCDMF. These results showed that ntCDMF could be a practical vaccine candidate.
Insights
A novel vaccine using a nontoxigenic Clostridium difficile membrane fraction (ntCDMF) significantly reduced C. difficile bacteria in mice and improved survival rates in hamsters, offering a promising approach to combat recurrent C. difficile infections.
Area of Science:
- Microbiology
- Immunology
- Infectious Diseases
Background:
- Recurrent Clostridium difficile infection (CDI) poses a significant clinical challenge despite standard antibiotic treatments.
- Existing therapies often fail to prevent the high rate of CDI recurrence.
- Nontoxigenic C. difficile membrane fraction (ntCDMF) showed potential as an in vitro vaccine antigen.
Purpose of the Study:
- To evaluate the in vivo efficacy of ntCDMF as a vaccine candidate against C. difficile.
- To assess the impact of ntCDMF immunization on C. difficile colonization and host survival.
Main Methods:
- Intrarectal immunization of mice with ntCDMF.
- Fecal C. difficile cell quantification in immunized and control mice.
- Challenge experiments in hamsters with C. difficile post-immunization.
- Monitoring survival rates in challenged hamsters.
Main Results:
- Intrarectal immunization with ntCDMF reduced C. difficile cell counts in mouse feces by approximately 99% compared to controls.
- Immunization with ntCDMF increased the survival rate of C. difficile-challenged hamsters by nearly 30%.
Conclusions:
- Nontoxigenic C. difficile membrane fraction (ntCDMF) demonstrates significant in vivo efficacy in preventing C. difficile colonization and reducing mortality.
- ntCDMF represents a practical and promising vaccine candidate for preventing and managing recurrent C. difficile infections.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Partial Fractions
Subcellular Fractionation
Differential Centrifugation
Differential centrifugation is...
Mixtures of Gases: Dalton's Law of Partial Pressures and Mole Fractions
Introduction to Membrane Proteins

